Efficacy of an Intranasal Testosterone Product
NCT01252745
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
22
Enrollment
INDUSTRY
Sponsor class
Conditions
Hypogonadism
Interventions
DRUG:
10.0 mg of Testosterone, 4.0% TID
DRUG:
13.5 mg of Testosterone, 4.5% B.I.D
DRUG:
11.25 mg of Testosterone, 4.5% T.I.D
Sponsor
Acerus Pharmaceuticals Corporation